Project Grant R01HL177288
Award Date 8/1/26
Completion Date 4/30/30
Dollars Obligated $760K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92697, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $767,953 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop biomimetic engineered heart valve leaflets that improve function and tissue remodeling. Work extends through March 31, 2030, and is performed in Pittsburgh, Pennsylvania. The project addresses clinical failures in tissue-engineered heart valves (TEHVs) deployed in pediatric patients, where pulmonary...
- The National Heart, Lung, and Blood Institute awarded $775,114 to the Research Institute At Nationwide Children's Hospital on June 12, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct preclinical evaluation of a cell-free tissue-engineered vascular graft designed for congenital heart surgery. The research addresses complications arising from prosthetic biomaterials currently used in surgical repair of complex congenital cardiac anomalies, including thromboembolic...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $163,160 on February 12, 2027, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize neoaortic valve biomechanics in the Ross procedure for congenital aortic valve disease. The research addresses durability limitations of the Ross procedure, in which a patient's healthy pulmonic valve is translocated to the aortic position. While the procedure offers a living valve replacement...
- The National Heart, Lung, and Blood Institute (NHLBI) at the Department of Health and Human Services awarded The Leland Stanford Junior University $755,271 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop, validate, and clinically evaluate a magnetic resonance imaging method for assessing blood flow hemodynamics in pediatric and young adult congenital heart disease patients. The project will augment 4D-flow MRI capabilities to enable direct...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Arkansas Children's Research Institute $801,261 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate partial heart transplantation (PHT) transplant biology in a piglet model. The project addresses a clinical barrier: current heart valve implants do not grow with children, requiring serial re-operations to replace outgrown devices. PHT delivers growing valve implants by...
- The National Heart, Lung, and Blood Institute awarded Bridgesource Medical, Corp. $320,727 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a right heart catheter device that uses pressure-volume loop analysis to identify which patients with tricuspid regurgitation will benefit from percutaneous valve repair procedures. The device addresses a critical clinical gap in patient selection for tricuspid valve interventions. Approximately 1.5 million...
- The National Heart, Lung, and Blood Institute awarded the University of California, Santa Barbara $130,955 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how viscoelastic properties and growth factor sequestering influence induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) using engineered biomaterials. The project examines the interplay between cardiac tissue viscoelasticity and growth factor signaling in both healthy and...
- The National Institutes of Health National Heart Lung and Blood Institute awarded the University of Texas at Austin $428,327 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop patient-specific, pre-procedural planning simulation tools for tricuspid valve repair. The project addresses tricuspid valve regurgitation, a condition affecting more than 1.6 million Americans, which is repaired in fewer than 10,000 patients annually due to low success...
- The National Institutes of Health's National Heart, Lung and Blood Institute awarded Fluidform Inc. a $766,107 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) from April 1, 2021 to March 31, 2022. The grant funds the development of an advanced bioprosthetic collagen heart valve using 3D printing techniques to recreate the collagen fiber architecture and mechanical properties of native heart valve leaflets. Fluidform will collaborate with Carnegie Mellon...
- The National Heart, Lung, and Blood Institute awarded Lazarus 3D, Inc. $400,016 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate PRE-SURE-CHD, a patient-specific preoperative surgical rehearsal and planning platform for congenital heart defects using 3D printing technology. The project develops synthetic materials that replicate the mechanical properties of cardiac tissue, creates patient-specific 3D-printed prototypes informed by CT...